TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03863249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALE AND ROOT PLANING
Description: SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADJUNTIVE ANTIBIOTICS
Description: The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADJUNTIVE ANTIBIOTICS
Description: The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADJUNTIVE ANTIBIOTICS
Description: The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MICROBIAL SAMPLING
Description: 1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MICROBIAL SAMPLING
Description: 1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MICROBIAL SAMPLING
Description: 1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy.
Study: NCT01191398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine (0.01mg/kg)
Description: Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate (0.01mg/kg)
Description: Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
Study: NCT03740945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of one placebo vaginal ovule at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone (DHEA)
Description: Daily administration of one prasterone vaginal ovule at bedtime
Study: NCT00509795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Study: NCT02188251

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Activamp

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00642876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Fusion and ATLANTIS™ Cervical Plate System
Description: The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE® Cervical Disc
Description: The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
Study: NCT01160042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage
Description: Glucophage 1000 mg tablets of Bristol-Myers Squibb
Study: NCT01135199

Intervention type: DRUG
Group type: OTHER
Intervention: pomalidomide (CC-4047
Study: NCT00509795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Study: NCT02675582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
Study: NCT02058706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orchiectomy
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orchiectomy
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Description: Undergo orchiectomy or receive LHRH analogue therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01935167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 600mg
Description: DW1029M 150mg 2 tablets b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg
Description: DW1029M 300mg 2 tablets b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets b.i.d.
Study: NCT03761264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odontopaste®
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
Study: NCT02789072

Intervention type: OTHER
Group type: OTHER
Intervention: central aortic pressure (measured in mmHg).
Description: Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed.
Study: NCT00369408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
Study: NCT02899104

Intervention type: DRUG
Intervention: Xofigo (Radium-223 dichloride, BAY88-8223)
Description: Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
Study: NCT03245294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epidural injection
Description: the pattern of pressure decrease from ligamentum flavum to epidural space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epidural injection
Description: the pattern of pressure decrease from ligamentum flavum to epidural space
Study: NCT02839655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Xi
Study: NCT03761264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulpdent
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
Study: NCT02521376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Entospletinib 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Entospletinib 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Entospletinib 100 mg tablet administered orally
Study: NCT01144507

Intervention type: PROCEDURE
Intervention: Abdominal Ultrasound
Description: To establish eligibility and/or markers regarding echo pattern types.

Intervention type: PROCEDURE
Intervention: Abdominal Ultrasound
Description: To establish eligibility and/or markers regarding echo pattern types.

Intervention type: PROCEDURE
Intervention: Abdominal Ultrasound
Description: To establish eligibility and/or markers regarding echo pattern types.

Intervention type: PROCEDURE
Intervention: Abdominal Ultrasound
Description: To establish eligibility and/or markers regarding echo pattern types.

Intervention type: OTHER
Intervention: Sample collection procedures
Description: Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects

Intervention type: OTHER
Intervention: Sample collection procedures
Description: Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects

Intervention type: OTHER
Intervention: Sample collection procedures
Description: Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects

Intervention type: OTHER
Intervention: Sample collection procedures
Description: Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
Study: NCT02931643

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High fat challenge breakfast
Description: In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat challenge breakfast with mixed-spices
Description: In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
Study: NCT01722526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human acid sphingomyelinase
Description: Administered intravenously every 2 weeks for 26 weeks
Study: NCT02061072

Intervention type: OTHER
Intervention: Population pharmacokinetic estimation
Description: Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
Study: NCT03922672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group piano training
Description: The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
Study: NCT02798432

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Total knee arthroplasty
Description: Use of an uncemented femoral component or a cemented femoral component randomly assigned.
Study: NCT03172078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: advanced endoscopic procedure
Description: The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: advanced endoscopic procedure
Description: The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
Study: NCT02348034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Dressing
Description: Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
Study: NCT02719691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
Study: NCT02798432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Use of an uncemented femoral component or a cemented femoral component randomly assigned.
Study: NCT02719691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
Study: NCT02798432

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEXGEN LPS total knee arthroplasty
Description: Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXGEN LPS total knee arthroplasty
Description: Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
Study: NCT00183560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy (MBCT)
Description: Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressants
Description: Participants continue on dosage of the antidepressant that was used to achieve clinical remission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus clinical management
Description: Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
Study: NCT02128061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT01147107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
Study: NCT02719691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
Study: NCT00483483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual and group HIV risk behavior counseling sessions
Description: Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education and support group
Description: general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
Study: NCT04371094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a device to facilitate endotracheal intubation
Description: a device to facilitate endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a device to facilitate endotracheal intubation
Description: a device to facilitate endotracheal intubation
Study: NCT02159898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoMAXX Endoluminal Valve Technology (EVT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoMAXX
Study: NCT01185314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Testing for mutation status
Description: EGFR mutation test
Study: NCT04510987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5
Description: Tablet, oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAY2433334 on dialysis treatment day
Description: Tablet, oral
Study: NCT01964157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
Study: NCT03788642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control LED shoe arm
Description: Patients with DFU will wear LED shoe 30 minutes once daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Shoe arm
Description: Patients with DFU will wear Laser shoe 30 minutes once daily
Study: NCT01283776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
Study: NCT03347526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Suspension, 1 mg/mL
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin
Description: Injectable + oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: oral